Ligand Pharma (LGND) Tops Q1 EPS by $1.42; Offers FY23 Guidance

Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $2.28, $1.42 better than the analyst estimate of $0.86. Revenue for the quarter came in at $44 million versus the consensus estimate of $32 million.

GUIDANCE:

Ligand Pharma sees FY2023 EPS of $4.60-$4.75, versus the consensus of $3.52. Ligand Pharma sees FY2023 revenue of $124-128 million, versus the consensus of $129 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Morgan Stanley Downgrades Infineon Technologies (IFX:GY) (IFNNY) to Equalweight
• Roth/MKM Downgrades eGain Corporation (EGAN) to Neutral